Linda M. Shuck, D.O.; Decision and Order, 55639-55641 [2017-25286]
Download as PDF
55639
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
While Congress also amended section
‘‘824(a) to add to the current bases for
denial, revocation, or suspension of
registration a finding that registration
would be inconsistent with the public
interest on the grounds specified in
[section] 823, which will include
consideration of the new factors added
by’’ the amendment, id. at 266–67,
Congress did not otherwise alter the text
of section 824(a), which makes clear
that the various paragraphs of this
provision are findings, each of which
provides an independent and adequate
ground to support agency action against
a registration, and not discretionary
factors to be considered by the Agency.
Indeed, Respondent points to nothing in
the language of section 824 or the CSA’s
legislative history to support his
position, which would fundamentally
alter the scope of the Agency’s authority
under section 824.
I therefore reject Respondent’s
contentions. Based on the ALJ’s finding
that Respondent is not currently
authorized to dispense controlled
substances in Mississippi, the State in
which he holds the DEA registration at
issue in this proceeding, I will adopt the
ALJ’s recommended order that I revoke
his registration.
DEPARTMENT OF JUSTICE
Order
ACTION:
Pursuant to the authority vested in me
by 21 U.S.C. 824(a), as well as 28 CFR
0.100(b), I order that DEA Certificate of
Registration No. AF2451261 issued to
Arnold E. Feldman, M.D., be, and it
hereby is, revoked. This Order is
effective immediately.9
SUMMARY:
Dated: November 13, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017–25287 Filed 11–21–17; 8:45 am]
BILLING CODE 4410–09–P
Drug Enforcement Administration
[Docket No. DEA–392]
Importer of Controlled Substances
Registration
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration as importers of various
classes of schedule I or II controlled
substances.
The
companies listed below applied to be
registered as importers of various basic
classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
and no requests for hearing were
submitted for these notices.
SUPPLEMENTARY INFORMATION:
Company
FR Docket
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Almac Clinical Services Incorp (ACSI) ........................................................................................................
Stepan Company .........................................................................................................................................
Fresenius Kabi USA, LLC ...........................................................................................................................
Cambrex Charles City .................................................................................................................................
Spex Certiprep Group, LLC .........................................................................................................................
Akorn, Inc ....................................................................................................................................................
Fisher Clinical Services, Inc ........................................................................................................................
Siegfried USA, LLC .....................................................................................................................................
Mylan Pharmaceuticals, Inc ........................................................................................................................
KVK-Tech, Inc .............................................................................................................................................
Cerilliant Corporation ...................................................................................................................................
Unither Manufacturing LLC .........................................................................................................................
Mylan Pharmaceuticals, Inc ........................................................................................................................
Catalent Centers, LLC .................................................................................................................................
Specgx LLC .................................................................................................................................................
Sharp Clinical Services, Inc ........................................................................................................................
Cody Laboratories, Inc ................................................................................................................................
Bellwyck Clinical Services ...........................................................................................................................
The Drug Enforcement
Administration (DEA) has considered
the factors in 21 U.S.C. 823, 952(a) and
958(a) and determined that the
registration of the listed registrants to
import the applicable basic classes of
schedule I or II controlled substances is
consistent with the public interest and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. The
DEA investigated each company’s
maintenance of effective controls
against diversion by inspecting and
testing each company’s physical
9 While the Mississippi Board Order was based on
the Louisiana Board’s Order, as noted in the former
Acting Administrator’s Decision and Order which
revoked Respondent’s Louisiana registration, the
Louisiana Board found proved the sixth charge of
the Administrative Complaint in that proceeding, in
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
Notice of registration.
security systems, verifying each
company’s compliance with state and
local laws, and reviewing each
company’s background and history.
Therefore, pursuant to 21 U.S.C.
952(a) and 958(a), and in accordance
with 21 CFR 1301.34, the DEA has
granted a registration as an importer for
schedule I or II controlled substances to
the above listed persons.
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
82
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
FR
37114
41054
41053
41055
42120
42117
42121
42117
42120
42119
43404
43571
43572
43569
43571
43572
45612
45613
Published
August 8, 2017.
August 29, 2017.
August 29, 2017.
August 29, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 6, 2017.
September 15, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 18, 2017.
September 29, 2017.
September 29, 2017.
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Linda M. Shuck, D.O.; Decision and
Order
BILLING CODE 4410–09–P
On July 25, 2017, the Assistant
Administrator, Diversion Control
Division, Drug Enforcement
Administration, issued an Order to
Show Cause to Linda M. Shuck
(Registrant), of Dobson, North Carolina.
The Show Cause Order proposed the
revocation of Registrant’s Certificate of
Registration, on the ground that she
that Respondent violated state law by
‘‘[p]rescribing, dispensing, or administering legally
controlled substances or any dependency-inducing
medication without legitimate medical justification
thereof or in other than a legal or legitimate
manner.’’ See 82 FR at 39618 n.8 (2017); see also
Mot. for Summ. Disp., Appendix B, at 22, 24
(Louisiana Board Order at 12, 14). For the same
reasons as those cited by the former Acting
Administrator, I find that the public interest
necessitates that this Order be effective
immediately. See also 21 CFR 1316.67.
Dated: November 16, 2017.
Demetra Ashley,
Acting Assistant Administrator.
[FR Doc. 2017–25284 Filed 11–21–17; 8:45 am]
PO 00000
Frm 00087
Fmt 4703
Sfmt 4703
E:\FR\FM\22NON1.SGM
22NON1
asabaliauskas on DSKBBXCHB2PROD with NOTICES
55640
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
‘‘do[es] not have authority to handle
controlled substances in the State of
North Carolina, the [S]tate in which [she
is] registered with the’’ Agency. GX 2,
at 1 (citing 21 U.S.C. 823(f) and
824(a)(3)).
As to the jurisdictional basis for the
proceeding, the Show Cause Order
alleged that Registrant is the holder of
a practitioner’s registration with
authority in schedules II through V,
under Certificate of Registration No.
BP4154023, at the registered location of
Carolina Heart Care, 651 S. Main Street,
Dobson, North Carolina. Id. The Order
further alleged that this registration
‘‘expires . . . on February 28, 2018.’’ Id.
As to the substantive ground for the
proceeding, the Show Cause Order
alleged that on June 23, 2017, the North
Carolina Medical Board suspended
Registrant’s medical license for six
months. Id. The Order alleged that
because of the Board’s action, Registrant
is ‘‘without authority to handle
controlled substances in . . . North
Carolina, the [S]tate in which [she is]
registered,’’ and that as a consequence,
her registration is subject to revocation.
Id. at 1–2 (citing cases).
The Show Cause Order notified
Registrant of her right to request a
hearing on the allegations or to submit
a written statement while waiving her
right to a hearing, the procedure for
electing either option, and the
consequence for failing to elect either
option. Id. at 2 (citing 21 CFR 1301.43).
In addition, the Show Cause Order
notified Registrant of her right to submit
a corrective action plan under 21 U.S.C.
824(c)(2)(C). Id. at 2–3.
On August 1, 2017, a DEA Special
Agent assigned to the Charlotte District
Office personally served the Show
Cause Order on Registrant. GX 3, at 1–
2 (Declaration of Special Agent). In a
letter dated August 3, 2017, Registrant
stated that she was ‘‘aware of the
current law regarding [her] DEA
Certificate’’ and that she did ‘‘not wish
to have a hearing on the issue.’’ GX 4.
Registrant further stated that her
‘‘medical license is suspend[ed] until
12–23–2017’’ and that she ‘‘will reapply
for [her] DEA certification after [her]
suspension is completed.’’ Id.
On September 8, 2017, the
Government submitted a Request for
Final Agency Action. Therein, the
Government seeks the revocation of
Registrant’s registration. As support for
the proposed action, the Government
submitted various exhibits, including a
Consent Order entered into by
Registrant and the North Carolina
Medical Board on May 23, 2017. See
GX3A, at 8.
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
Based on Registrant’s letter of August
3, 2017, I find that Registrant has
waived her right to a hearing on the
allegations of the Show Cause Order. 21
CFR 1301.43. I therefore issue this
Decision and Order based on relevant
evidence submitted by the Government.
I make the following findings.
Findings
Registrant is the holder of DEA
Certificate of Registration No.
BP4154023, pursuant to which she is
authorized to dispense controlled
substances in schedules II through V, at
the registered address of Carolina Heart
Care, 651 S. Main St., Dobson, North
Carolina. GX 1. Registrant is also the
holder of DATA-Waiver Identification
No. XP4154023, pursuant to which she
is authorized to prescribe schedule III
through V ‘‘narcotic drug[s] approved by
the Food and Drug Administration
specifically for use in maintenance or
detoxification treatment’’ to up to 100
patients. GX 1; see also 21 CFR
1306.04(c).
Registrant is also the holder of a
license to practice medicine and surgery
issued by the North Carolina Medical
Board. However, on May 23, 2017,
Registrant entered into a Consent Order
with the Board. GX 3, Appendix A, at
8. The Board’s Order found that in
September 2014, Registrant and the
Board had entered a previous Consent
Order ‘‘based on findings that [she] had
failed to conform to the standards of
acceptable and prevailing medical
practice in her care of five patients that
she treated for chronic pain.’’ Id. at 2.
The Board further found that while
Registrant ‘‘underwent the required
[comprehensive professional]
assessment, [she] still has failed to
complete any remediation
recommended by the assessment center
in a timely manner.’’ Id.
The Board’s Order also found that, in
April 2016, it had received information
regarding Registrant’s prescribing of
opiates to four patients, including one
who died due to ‘‘opioid toxicity.’’ Id.
The Board further found that ‘‘an
independent medical expert’’ had
reviewed the medical records of the four
patients and opined that Registrant’s
‘‘diagnosis, treatment, and overall care
in all four . . . cases failed to conform
to the standards of acceptable and
prevailing medical practice in North
Carolina.’’ Id.
Finally, the Board found that, ‘‘[o]n
December 6, 2016, [Registrant] entered
into an Interim Partial Non-Practice
Agreement restricting her prescribing of
all controlled substances.’’ Id. at 3. The
Board further found that Registrant
issued controlled substance
PO 00000
Frm 00088
Fmt 4703
Sfmt 4703
prescriptions to patients in violation of
the Interim Partial Non-Practice
Agreement. Id.
With respect to her ‘‘care and
treatment of’’ the four patients, the
Board concluded as a matter of law that
Registrant ‘‘fail[ed] to conform to the
standards of acceptable and prevailing
medical practice.’’ Id. at 4 (citing N.C.
Gen. Stat. SEC. 90–14(a)(6)). The Board
also concluded as a matter of law that
Registrant’s ‘‘issuance of controlled
substance prescriptions in violation of a
restriction contained in the December
2016 Interim Partial Non-Practice
Agreement . . . constitutes
unprofessional conduct.’’ Id. (citing N.C.
Gen. Stat. SEC. 90–14(a)(6)).
The Board and Registrant agreed to
resolve the matter by suspending her
medical license for a period of six
months ‘‘from June 23, 2017[] until
December 23, 2017.’’ Id. at 5. While the
Board and Registrant agreed that she
‘‘may return to the active practice of
medicine on December 24, 2017, subject
to the provisions contained in this . . .
Order,’’ the provisions include that she
‘‘shall not prescribe controlled
substances except for a patient who has
been admitted to a hospital where [she]
has active clinical privileges.’’ Id. The
provisions also include that ‘‘[o]nce the
patient has been discharged, [she] shall
not prescribe controlled substances for
those patients who received such
medications pursuant to’’ the above
provision. Id. at 6.
Moreover, Registrant’s ability to
resume practicing medicine is also
subject to the condition that she
‘‘complete a five . . . day board
certification review course in Internal
Medicine.’’ 1 Id. Thus, while the
suspension may expire in less than six
weeks, it is far from certain that she will
be able to resume practicing medicine
(even subject to the limitations on her
authority to prescribe), and absent
evidence that she has completed the
board certification review course, the
restriction on her ability to resume
practicing takes on the characteristic of
a suspension of indefinite duration.
Based on the above, I find that
Registrant is currently without authority
1 According to the online records of the North
Carolina Medical Board, of which I take official
notice, the suspension of Registrant’s medical
license remains in effect as of the date of this
Decision and Order. See 5 U.S.C. 556(e). Registrant
may dispute this finding by filing a properly
supported motion for reconsideration within 10
business days of the date of this Order with the
Office of the Administrator. Registrant may also
provide evidence that she has completed the fiveday board certification review course. Registrant
must serve a copy of any such motion on the
Government.
E:\FR\FM\22NON1.SGM
22NON1
55641
Federal Register / Vol. 82, No. 224 / Wednesday, November 22, 2017 / Notices
to dispense controlled substances under
the laws of the State of North Carolina.
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the
Attorney General is authorized to
suspend or revoke a registration issued
under section 823, ‘‘upon a finding that
the Registrant . . . has had his State
license . . . suspended [or] revoked
. . . by competent State authority and is
no longer authorized by State law to
engage in the . . . dispensing of
controlled substances.’’ Also, DEA has
held repeatedly that the possession of
authority to dispense controlled
substances under the laws of the State
in which a practitioner engages in
professional practice is a fundamental
condition for obtaining and maintaining
a practitioner’s registration. See, e.g.,
James L. Hooper, 76 FR 71371 (2011),
pet. for rev. denied, 481 Fed Appx. 826
(4th Cir. 2012); Frederick Marsh
Blanton, 43 FR 27616 (1978).
This rule derives from the text of two
provisions of the CSA. First, Congress
defined ‘‘the term ‘practitioner’ [to]
mean[] a . . . physician . . . or other
person licensed, registered or otherwise
permitted, by . . . the jurisdiction in
which [s]he practices . . . to distribute,
dispense, [or] administer . . . a
controlled substance in the course of
professional practice.’’ 21 U.S.C.
802(21). Second, in setting the
requirements for obtaining a
practitioner’s registration, Congress
directed that ‘‘[t]he Attorney General
shall register practitioners . . . if the
applicant is authorized to dispense . . .
controlled substances under the laws of
the State in which [s]he practices.’’ 21
U.S.C. 823(f). Because Congress has
clearly mandated that a physician
possess state authority in order to be
deemed a practitioner under the Act,
DEA has held that revocation of a
practitioner’s registration is the
appropriate sanction whenever she is no
longer authorized to dispense controlled
substances under the laws of the State
in which she practices medicine. See,
e.g., Calvin Ramsey, 76 FR 20034, 20036
(2011); Sheran Arden Yeates, M.D., 71
FR 39130, 39131 (2006); Dominick A.
Ricci, 58 FR 51104, 51105 (1993); Bobby
Watts, 53 FR 11919, 11920 (1988); see
also Hooper v. Holder, 481 Fed. Appx.
at 828.
As a consequence of the Consent
Order which Registrant entered into
with the Board, she is not currently
authorized to dispense controlled
substances in North Carolina, the State
in which she is registered with the
Agency. Because the CSA makes clear
that the possession of authority to
dispense controlled substances under
the laws of the State in which a
practitioner engages in professional
practice is a fundamental condition for
both obtaining and maintaining a
practitioner’s registration, it is of no
consequence that the suspension is of a
finite duration. See Hooper v. Holder,
481 F. App’x at 828 (upholding
revocation of a physician’s registration
as based on a reasonable interpretation
of the CSA, notwithstanding that the
physician’s medical license was subject
to a suspension of known duration); see
also James L. Hooper, 76 FR 71371,
71371–72 (2011). Rather, what matters
for the purposes of the CSA is that
Registrant is not currently authorized to
dispense controlled substances in North
Carolina. See Hooper, 76 FR at 71371
(quoting Anne Lazar Thorn, 62 FR
12847, 12848 (1997) (‘‘the controlling
question . . . is whether the
Respondent is currently authorized to
handle controlled substances in the
state’’)). Indeed, it is by no means clear
that Registrant will even be able to
resume the practice of medicine
following the ending date of the
suspension given the requirement that
she complete the required five-day
board certification review course.2
Therefore, she is not entitled to
maintain her registration in that State.
Accordingly, I will order that her
registration and her DATA-Waiver
Identification number be revoked.
Order
Pursuant to the authority vested in me
by 21 U.S.C. 824(a) and 28 CFR 0.100(b),
I order that DEA Certificate of
Registration No. BP4154023, issued to
Linda M. Shuck, be, and it hereby is,
revoked. I further order that DATAWaiver Identification No. XP4154023,
issued to Linda M. Shuck, be, and it
hereby is, revoked. This order is
effective immediately.3
Dated: November 13, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017–25286 Filed 11–21–17; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
[Docket No. DEA–392]
Bulk Manufacturer of Controlled
Substances Registration
ACTION:
Registrants listed below have
applied for and been granted
registration by the Drug Enforcement
Administration as bulk manufacturers of
various classes of schedule I and II
controlled substances.
SUPPLEMENTARY INFORMATION: The
companies listed below applied to be
registered as manufacturers of various
basic classes of controlled substances.
Information on previously published
notices is listed in the table below. No
comments or objections were submitted
for these notices.
SUMMARY:
Company
FR Docket
asabaliauskas on DSKBBXCHB2PROD with NOTICES
Cayman Chemical Company .......................................................................................................................
AMRI Rensselaer, Inc .................................................................................................................................
Organic Consultants, Inc .............................................................................................................................
Isosciences, LLC .........................................................................................................................................
Cody Laboratories, Inc ................................................................................................................................
Noramco, Inc ...............................................................................................................................................
Stepan Company .........................................................................................................................................
2 Indeed, as found above, even if she completes
the course and returns to practice, under the
Consent Order, she is prohibited from prescribing
controlled substances outside of a hospital where
she ‘‘has active clinical privileges.’’ GX 3, Appendix
A, at 5. As this revocation does not impose any time
VerDate Sep<11>2014
18:57 Nov 21, 2017
Jkt 244001
bar on Registrant’s ability to reapply, she can apply
for a new registration upon being allowed to return
to practice.
3 Based on the North Carolina Board’s findings
that Registrant prescribed controlled substances in
PO 00000
Frm 00089
Notice of registration.
Fmt 4703
Sfmt 4703
82
82
82
82
82
82
82
FR
FR
FR
FR
FR
FR
FR
34691
34695
34696
35546
41054
41055
42119
Published
July 26, 2017.
July 26, 2017.
July 26, 2017.
July 31, 2017.
August 29, 2017.
August 29, 2017.
September 6, 2017.
violation of the Interim Partial Non-Practice
Agreement, I find that the public interest
necessitates that this Order be effective
immediately. 21 CFR 1316.67.
E:\FR\FM\22NON1.SGM
22NON1
Agencies
[Federal Register Volume 82, Number 224 (Wednesday, November 22, 2017)]
[Notices]
[Pages 55639-55641]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-25286]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Linda M. Shuck, D.O.; Decision and Order
On July 25, 2017, the Assistant Administrator, Diversion Control
Division, Drug Enforcement Administration, issued an Order to Show
Cause to Linda M. Shuck (Registrant), of Dobson, North Carolina. The
Show Cause Order proposed the revocation of Registrant's Certificate of
Registration, on the ground that she
[[Page 55640]]
``do[es] not have authority to handle controlled substances in the
State of North Carolina, the [S]tate in which [she is] registered with
the'' Agency. GX 2, at 1 (citing 21 U.S.C. 823(f) and 824(a)(3)).
As to the jurisdictional basis for the proceeding, the Show Cause
Order alleged that Registrant is the holder of a practitioner's
registration with authority in schedules II through V, under
Certificate of Registration No. BP4154023, at the registered location
of Carolina Heart Care, 651 S. Main Street, Dobson, North Carolina. Id.
The Order further alleged that this registration ``expires . . . on
February 28, 2018.'' Id.
As to the substantive ground for the proceeding, the Show Cause
Order alleged that on June 23, 2017, the North Carolina Medical Board
suspended Registrant's medical license for six months. Id. The Order
alleged that because of the Board's action, Registrant is ``without
authority to handle controlled substances in . . . North Carolina, the
[S]tate in which [she is] registered,'' and that as a consequence, her
registration is subject to revocation. Id. at 1-2 (citing cases).
The Show Cause Order notified Registrant of her right to request a
hearing on the allegations or to submit a written statement while
waiving her right to a hearing, the procedure for electing either
option, and the consequence for failing to elect either option. Id. at
2 (citing 21 CFR 1301.43). In addition, the Show Cause Order notified
Registrant of her right to submit a corrective action plan under 21
U.S.C. 824(c)(2)(C). Id. at 2-3.
On August 1, 2017, a DEA Special Agent assigned to the Charlotte
District Office personally served the Show Cause Order on Registrant.
GX 3, at 1-2 (Declaration of Special Agent). In a letter dated August
3, 2017, Registrant stated that she was ``aware of the current law
regarding [her] DEA Certificate'' and that she did ``not wish to have a
hearing on the issue.'' GX 4. Registrant further stated that her
``medical license is suspend[ed] until 12-23-2017'' and that she ``will
reapply for [her] DEA certification after [her] suspension is
completed.'' Id.
On September 8, 2017, the Government submitted a Request for Final
Agency Action. Therein, the Government seeks the revocation of
Registrant's registration. As support for the proposed action, the
Government submitted various exhibits, including a Consent Order
entered into by Registrant and the North Carolina Medical Board on May
23, 2017. See GX3A, at 8.
Based on Registrant's letter of August 3, 2017, I find that
Registrant has waived her right to a hearing on the allegations of the
Show Cause Order. 21 CFR 1301.43. I therefore issue this Decision and
Order based on relevant evidence submitted by the Government. I make
the following findings.
Findings
Registrant is the holder of DEA Certificate of Registration No.
BP4154023, pursuant to which she is authorized to dispense controlled
substances in schedules II through V, at the registered address of
Carolina Heart Care, 651 S. Main St., Dobson, North Carolina. GX 1.
Registrant is also the holder of DATA-Waiver Identification No.
XP4154023, pursuant to which she is authorized to prescribe schedule
III through V ``narcotic drug[s] approved by the Food and Drug
Administration specifically for use in maintenance or detoxification
treatment'' to up to 100 patients. GX 1; see also 21 CFR 1306.04(c).
Registrant is also the holder of a license to practice medicine and
surgery issued by the North Carolina Medical Board. However, on May 23,
2017, Registrant entered into a Consent Order with the Board. GX 3,
Appendix A, at 8. The Board's Order found that in September 2014,
Registrant and the Board had entered a previous Consent Order ``based
on findings that [she] had failed to conform to the standards of
acceptable and prevailing medical practice in her care of five patients
that she treated for chronic pain.'' Id. at 2. The Board further found
that while Registrant ``underwent the required [comprehensive
professional] assessment, [she] still has failed to complete any
remediation recommended by the assessment center in a timely manner.''
Id.
The Board's Order also found that, in April 2016, it had received
information regarding Registrant's prescribing of opiates to four
patients, including one who died due to ``opioid toxicity.'' Id. The
Board further found that ``an independent medical expert'' had reviewed
the medical records of the four patients and opined that Registrant's
``diagnosis, treatment, and overall care in all four . . . cases failed
to conform to the standards of acceptable and prevailing medical
practice in North Carolina.'' Id.
Finally, the Board found that, ``[o]n December 6, 2016,
[Registrant] entered into an Interim Partial Non-Practice Agreement
restricting her prescribing of all controlled substances.'' Id. at 3.
The Board further found that Registrant issued controlled substance
prescriptions to patients in violation of the Interim Partial Non-
Practice Agreement. Id.
With respect to her ``care and treatment of'' the four patients,
the Board concluded as a matter of law that Registrant ``fail[ed] to
conform to the standards of acceptable and prevailing medical
practice.'' Id. at 4 (citing N.C. Gen. Stat. SEC. 90-14(a)(6)). The
Board also concluded as a matter of law that Registrant's ``issuance of
controlled substance prescriptions in violation of a restriction
contained in the December 2016 Interim Partial Non-Practice Agreement .
. . constitutes unprofessional conduct.'' Id. (citing N.C. Gen. Stat.
SEC. 90-14(a)(6)).
The Board and Registrant agreed to resolve the matter by suspending
her medical license for a period of six months ``from June 23, 2017[]
until December 23, 2017.'' Id. at 5. While the Board and Registrant
agreed that she ``may return to the active practice of medicine on
December 24, 2017, subject to the provisions contained in this . . .
Order,'' the provisions include that she ``shall not prescribe
controlled substances except for a patient who has been admitted to a
hospital where [she] has active clinical privileges.'' Id. The
provisions also include that ``[o]nce the patient has been discharged,
[she] shall not prescribe controlled substances for those patients who
received such medications pursuant to'' the above provision. Id. at 6.
Moreover, Registrant's ability to resume practicing medicine is
also subject to the condition that she ``complete a five . . . day
board certification review course in Internal Medicine.'' \1\ Id. Thus,
while the suspension may expire in less than six weeks, it is far from
certain that she will be able to resume practicing medicine (even
subject to the limitations on her authority to prescribe), and absent
evidence that she has completed the board certification review course,
the restriction on her ability to resume practicing takes on the
characteristic of a suspension of indefinite duration. Based on the
above, I find that Registrant is currently without authority
[[Page 55641]]
to dispense controlled substances under the laws of the State of North
Carolina.
---------------------------------------------------------------------------
\1\ According to the online records of the North Carolina
Medical Board, of which I take official notice, the suspension of
Registrant's medical license remains in effect as of the date of
this Decision and Order. See 5 U.S.C. 556(e). Registrant may dispute
this finding by filing a properly supported motion for
reconsideration within 10 business days of the date of this Order
with the Office of the Administrator. Registrant may also provide
evidence that she has completed the five-day board certification
review course. Registrant must serve a copy of any such motion on
the Government.
---------------------------------------------------------------------------
Discussion
Pursuant to 21 U.S.C. 824(a)(3), the Attorney General is authorized
to suspend or revoke a registration issued under section 823, ``upon a
finding that the Registrant . . . has had his State license . . .
suspended [or] revoked . . . by competent State authority and is no
longer authorized by State law to engage in the . . . dispensing of
controlled substances.'' Also, DEA has held repeatedly that the
possession of authority to dispense controlled substances under the
laws of the State in which a practitioner engages in professional
practice is a fundamental condition for obtaining and maintaining a
practitioner's registration. See, e.g., James L. Hooper, 76 FR 71371
(2011), pet. for rev. denied, 481 Fed Appx. 826 (4th Cir. 2012);
Frederick Marsh Blanton, 43 FR 27616 (1978).
This rule derives from the text of two provisions of the CSA.
First, Congress defined ``the term `practitioner' [to] mean[] a . . .
physician . . . or other person licensed, registered or otherwise
permitted, by . . . the jurisdiction in which [s]he practices . . . to
distribute, dispense, [or] administer . . . a controlled substance in
the course of professional practice.'' 21 U.S.C. 802(21). Second, in
setting the requirements for obtaining a practitioner's registration,
Congress directed that ``[t]he Attorney General shall register
practitioners . . . if the applicant is authorized to dispense . . .
controlled substances under the laws of the State in which [s]he
practices.'' 21 U.S.C. 823(f). Because Congress has clearly mandated
that a physician possess state authority in order to be deemed a
practitioner under the Act, DEA has held that revocation of a
practitioner's registration is the appropriate sanction whenever she is
no longer authorized to dispense controlled substances under the laws
of the State in which she practices medicine. See, e.g., Calvin Ramsey,
76 FR 20034, 20036 (2011); Sheran Arden Yeates, M.D., 71 FR 39130,
39131 (2006); Dominick A. Ricci, 58 FR 51104, 51105 (1993); Bobby
Watts, 53 FR 11919, 11920 (1988); see also Hooper v. Holder, 481 Fed.
Appx. at 828.
As a consequence of the Consent Order which Registrant entered into
with the Board, she is not currently authorized to dispense controlled
substances in North Carolina, the State in which she is registered with
the Agency. Because the CSA makes clear that the possession of
authority to dispense controlled substances under the laws of the State
in which a practitioner engages in professional practice is a
fundamental condition for both obtaining and maintaining a
practitioner's registration, it is of no consequence that the
suspension is of a finite duration. See Hooper v. Holder, 481 F. App'x
at 828 (upholding revocation of a physician's registration as based on
a reasonable interpretation of the CSA, notwithstanding that the
physician's medical license was subject to a suspension of known
duration); see also James L. Hooper, 76 FR 71371, 71371-72 (2011).
Rather, what matters for the purposes of the CSA is that Registrant is
not currently authorized to dispense controlled substances in North
Carolina. See Hooper, 76 FR at 71371 (quoting Anne Lazar Thorn, 62 FR
12847, 12848 (1997) (``the controlling question . . . is whether the
Respondent is currently authorized to handle controlled substances in
the state'')). Indeed, it is by no means clear that Registrant will
even be able to resume the practice of medicine following the ending
date of the suspension given the requirement that she complete the
required five-day board certification review course.\2\ Therefore, she
is not entitled to maintain her registration in that State.
Accordingly, I will order that her registration and her DATA-Waiver
Identification number be revoked.
---------------------------------------------------------------------------
\2\ Indeed, as found above, even if she completes the course and
returns to practice, under the Consent Order, she is prohibited from
prescribing controlled substances outside of a hospital where she
``has active clinical privileges.'' GX 3, Appendix A, at 5. As this
revocation does not impose any time bar on Registrant's ability to
reapply, she can apply for a new registration upon being allowed to
return to practice.
---------------------------------------------------------------------------
Order
Pursuant to the authority vested in me by 21 U.S.C. 824(a) and 28
CFR 0.100(b), I order that DEA Certificate of Registration No.
BP4154023, issued to Linda M. Shuck, be, and it hereby is, revoked. I
further order that DATA-Waiver Identification No. XP4154023, issued to
Linda M. Shuck, be, and it hereby is, revoked. This order is effective
immediately.\3\
---------------------------------------------------------------------------
\3\ Based on the North Carolina Board's findings that Registrant
prescribed controlled substances in violation of the Interim Partial
Non-Practice Agreement, I find that the public interest necessitates
that this Order be effective immediately. 21 CFR 1316.67.
Dated: November 13, 2017.
Robert W. Patterson,
Acting Administrator.
[FR Doc. 2017-25286 Filed 11-21-17; 8:45 am]
BILLING CODE 4410-09-P